Over-activity of the immune system is a primary cause of many diseases, both common and rare. Afecta is focused on developing new drugs to selectively suppress specific pro-inflammatory pathways involved in dermatologic disorders as well as other related diseases. We have used a novel technology platform, PharmetRx™, to discover several classes of new small molecules based on compounds that are proven to be safe. We are using novel formulation technologies to improve delivery of these lead drugs to specifically and directly target the affected tissues, thus minimizing systemic effects. These “de-risked” lead drug candidates are being moved into our clinical development pipeline.
Sustained Dermal Release™
Our highly stable, non-toxic, high capacity micro-carrier technology.
Sustained Dermal Release™ (SDR™) is a proprietary method for topical application of one or more drugs in combination to the epidermis. The active pharmaceutical ingredient is then released in a controlled manner into the dermal layers. This produces higher levels of the active ingredient in the skin without systemic exposure.